Action SABS SAB BIOTHERAPEUTICS, INC.
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Autres langues SAB Biotherapeutics, Inc.

Actions

SABS

US78397T2024

Marché Fermé - Nasdaq
Autres places de cotation
 22:30:00 25/04/2024 		Varia. 5j. Varia. 1 janv.
4,01 USD -8,86 % Graphique intraday de SAB Biotherapeutics, Inc. -10,09 % -41,67 %
16/04 SAB Biotherapeutics, Inc. fait le point sur l'essai SAB-142 CI
02/04 SAB BIOTHERAPEUTICS, INC. : HC Wainwright à l'achat ZM

Autres langues

Recherche
Voir les résultats
Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !
Inscription 100% Gratuite
SAB Biotherapeutics Provides SAB-142 Trial Update
SAB Biotherapeutics, Inc. Provides SAB-142 Trial Update
SAB Biotherapeutics : Regulation FD Disclosure - Form 8-K
SAB Biotherapeutics to Present at INNODIA Annual Meeting
SAB Biotherapeutics to Present at the Needham Virtual Healthcare Conference
SAB Biotherapeutics Reports Full Year 2023 Operating and Financial Results
SAB Biotherapeutics : Reports Full Year 2023 Operating and Financial Results March 29, 2024 - Form 8-K
SAB Biotherapeutics Reports Full Year 2023 Operating and Financial Results
SAB Biotherapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
SAB Biotherapeutics, Navy Medical Research Command Initiate Safety Study for Influenza Treatment; Shares Decline
SAB Biotherapeutics Announces Clinical Partnership with Naval Medical Research Center to Advance Potential Influenza Treatment
Sab Biotherapeutics, Inc. Announces Clinical Partnership with Naval Medical Research Center to Advance Potential Influenza Treatment
SAB Biotherapeutics to Present at the BIO CEO and Investor Conference
SAB Biotherapeutics to Present at the BIO CEO & Investor Conference
SAB Biotherapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
SAB Biotherapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
SAB Biotherapeutics Executive Chairman Samuel Reich Adds CEO Role
SAB Biotherapeutics Announces Executive Leadership Change
SAB Biotherapeutics, Inc. Announces CEO Changes
SAB Biotherapeutics Regains Nasdaq Compliance
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action SABS
  4. Actualités SAB Biotherapeutics, Inc.
  5. Autres langues